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Abstract
The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-phar-
macological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an 
intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de 
novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect 
observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly 
suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication 
or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the 
important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options 
and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect 
when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching 
patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals’ understanding of 
biosimilars and utilising a managed switching programme.
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Key Points 
The nocebo effect is a non-pharmacological effect caus-
ing a negative subjective outcome on treatment, which 
cannot be objectivised. It is a known but often disre-
garded phenomenon, impacting patient outcomes across 
different therapy areas.
Specific areas of nocebo-related research focusing on 
reference biologic to biosimilar biologic switching has 
rekindled interest in the nocebo effect and its clinical 
implications.
A lack of knowledge regarding biosimilars is causing 
reticence to switch; improving communication strategies 
when transitioning patients to a biosimilar may improve 
clinical outcomes and discontinuation rates. A coherent 
approach across the full healthcare team is required to 
realise the cost-saving potential of biosimilars.
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Kesselheim et al. in 2010 reported how observational studies 
have identified negative trends attributed to changes in epi-
lepsy seizure control after transition to generic drugs [10]. 
In contrast, evidence from available randomised controlled 
trials was unable to provide an association between loss 
of seizure control and generic substitution [10]. Findings 
from the observational studies may be due to unnecessary 
concerns from patients or healthcare professionals (HCPs) 
about the effectiveness of generic anti-epileptic drugs after 
recent transition [10]. Today we face a similar situation with 
biosimilars.
Biosimilars provide cost-effective alternatives to refer-
ence biologics, leading to an increase in physician treatment 
options and patient access to effective biologic treatment. 
However, considering a switch can be daunting [19], and 
it is the responsibility of the physician to ensure patients 
are fully confident in understanding the benefits and risks, 
so that they can help their patients make informed choices 
without bias [19]. Where confidence in biosimilars is not 
built through traditional clinical training, knowledge of and 
access to high-quality data, and subsequently unsuccessfully 
communicated to patients, the nocebo effect is a real risk 
with possible negative implications (Table 2) [20].
3  Nocebo Effect when Switching 
to Biosimilars
The NOR-SWITCH study, a 52-week, randomised, double-
blind, non-inferiority, phase IV study, was conducted in adult 
patients with axial spondyloarthritis, rheumatoid arthritis 
(RA), psoriatic arthritis (PsA), Crohn’s disease, ulcerative 
colitis, or psoriasis. Patients with informed consent were 
randomised to either continue originator infliximab (IFX) 
or to transition to biosimilar infliximab (CT-P13) [21]. This 
trial demonstrated that switching from IFX to CT-P13 was 
non-inferior to continued treatment with IFX [21]. However, 
discordance in patient and physician outcome reporting was 
observed, which is a phenomenon previously reported [22]. 
Using patient-reported outcome (PRO) measures such as 
patient global assessment—one of the most widely reported 
PROs in RA—allows a more holistic assessment of disease 
and provides the patients’ perspective on aspects of their 
condition [23]. Figure 2 highlights disease experience also 
Fig. 1  Placebo versus nocebo [2, 3]
1 Introduction
“But if thought corrupts language, language can also 
corrupt thought.” George Orwell [1].
The significant power of the physician–patient relation-
ship has been documented for centuries. The power of words 
within that relationship is crucial. Words have the power 
to harm or to heal, and how one word is said, the empha-
sis placed on it, and both verbal and non-verbal cues are 
important. The same may be said of the relationship between 
the physician and the patient, previous patient experiences, 
preconceptions, and even the setting of the conversation and 
health state of the patient at the time. Each of these factors 
contribute to the understanding that a patient has following 
a consultation and their expectations of the medication that 
they receive, both of which can influence whether a nocebo 
effect is likely to occur [2].
2  What is the Nocebo Effect?
As a result of physician–patient communication and patient 
treatment expectations, two clinical phenomena can be 
described: the placebo effect and the nocebo effect [2, 3]. 
The placebo effect is a well-accepted phenomenon and has 
been widely studied [4]; it can provide clear clinical ben-
efits, such as pain management, as was reported in 1978 
[5]. The placebo effect conveys positive beliefs and benefi-
cial outcomes from a positive communication about a sham 
treatment or medication that the patient is/will be receiving 
[2]. The nocebo effect is defined as the incitement or the 
worsening of symptoms induced by any negative attitude 
from non-pharmacological therapeutic intervention, sham, 
or active therapies (Fig. 1) [2, 3]. When a patient anticipates 
a negative effect associated with an intervention, medication 
or change in medication, they may then experience either an 
increase in this effect or experience it de novo [2, 3].
Although less is known about the nocebo effect than the 
placebo effect, a recent literature review (Table 1) highlights 
the nocebo effect across at least ten disease areas, strongly 
suggesting this is not a ‘new’ phenomenon [3]. Nocebo 
effects can play an important role when introducing a medi-
cation or changing an established medication. There have 
been interesting investigations concerning treatment of pain, 
epilepsy, and itch showing the influence of physician–patient 
communication [6–8]. Gagne et al. in 2010 were the first 
to document that anti-epileptic drug prescription refilling 
may be associated with an elevated risk of seizure-related 
events, indicating a pattern independent of any transitioning 
issues [7]. Additionally, the introduction of generic medi-
cines brought new insights concerning the influence of nega-
tive expectations on the rate of adverse events (AEs) [9]. 
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worsened under reference treatment, stressing the necessity 
for adequate controls when interpreting results regarding the 
response to change in treatment in single-arm studies.
Although data from controlled blinded trials have shown 
biosimilars used for treatment of autoimmune diseases to 
be equivalent to their reference biologic, data on open-
label transitioning to biosimilars are scarce. BIO-SPAN, 
the abstract of which was presented at EULAR 2017, and 
BIO-SWITCH are two such observational studies [24, 25]. 
These two studies (BIO-SWITCH, from IFX to CT-P13, and 
BIO-SPAN, from reference etanercept [ETN] to biosimilar 
etanercept [SB4]) were conducted in patients with rheumatic 
disease using different communication strategies to assess 
how an effective communication strategy may impact on 
reducing the nocebo effect [24, 25]. In patients transitioning 
from ETN to SB4, communication around transitioning was 
enhanced with additional information on the lower costs of 
treatment and data regarding potentially fewer injection-site 
reactions. During 84 person-years of follow-up, 47 patients 
discontinued CT-P13 (56/100 person-years; 26% due to inef-
ficacy, 74% due to AEs). In contrast, 36 patients discon-
tinued SB4 during 230 person-years of follow-up (16/100 
person-years; 53% due to inefficacy, 42% due to AEs and 
5% due to remission) [24–26], demonstrating that improved 
communication resulted in much higher acceptance and per-
sistence rates in those switching from a reference product to 
a biosimilar [24–26]. These data are also supported by five 
recent studies in which authors suggest a nocebo influence 
has occurred when patients were switched from reference 
biologics to biosimilars (Table 3).
In these examples, where effectiveness and safety were 
generally maintained, the authors hint to the nocebo effect to 
explain some of the observations where patient expectations 
may have affected the outcome, and not the pharmacological 
Table 1  Examples of nocebo effect described in literature [3]
Copyright © 2016, the authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society 
and American Society for Pharmacology and Experimental Therapeutics
AE adverse event, CV cardiovascular, HCP healthcare professional, PTSD post-traumatic stress disorder
Area of study Conclusion
Pain: migraine and 
tension-type headache
Nocebo is prevalent in clinical trials for primary headaches, particularly in preventive treatment studies. Dropouts 
due to the nocebo effect may confound the interpretation of many clinical trials [11]
Pain: neuropathic pain A strong nocebo effect may be adversely affecting adherence and efficacy of current treatments for neuropathic pain 
in clinical practice [12]
Pain: fibromyalgia Nocebo effects substantially accounted for AEs in drug trials of fibromyalgia [2]
Drug: vaccines Patients and HCPs tend to preferentially report the symptoms of the disease or symptoms of the organs affected by 
the disease. This bias could generate false safety signals [13]
Drug: allergology Oral provocation test can be biased by the nocebo effect. Frequency comparable with the frequency of the placebo 
effect [14]
Drug: generic substitution Generic drugs may be associated with more side effects because of negative expectations. The general public and 
medical practitioners alike often hold negative views of generic medicines [9]
Other: lactose intolerance Symptoms reported by patients during a negative breath test cannot be attributed to a false-negative test. Nocebo 
effect is likely implicated [15]
Other: CV disease Negative expectations can have an impact on morbidity [16]
Other: Parkinson’s disease Motor performance can be modulated in two opposite directions by placebos and nocebos, and this modulation 
occurs on the basis of positive and negative expectations about motor performance [17]
Other: PTSD Learning what symptoms to expect may lead to an increase in self-directed focus of attention that may cause more 
of those symptoms to appear [18]
Table 2  Consequences of the nocebo effect [19, 20]
Non-adherence
Wasted medication
Increased financial burden of correcting suboptimal responses/disease relapse
Increased symptom burden and associated psychological distress
The addition of other medications to manage side effects, leading to polypharmacy, higher treatment costs and more complex daily regimens
Loss of patient trust/breakdown in the physician–patient relationship
Increased re-switching rates
Discontinuation rates in clinical trials or registries affecting interpretation of results, and evaluation and development of novel therapies
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properties of the agents involved. Considering the wide-
spread influence the nocebo effect can have, interest in how 
to negate this effect to improve clinical outcomes and reduce 
cost burdens is increasing [2, 3, 32].
4  Overcoming the Nocebo Effect: Triggers 
and Practical Guidance for Clinical 
Practice
It is clear from the literature that there are three key triggers 
for the nocebo effect, which may offer possible solutions to 
overcoming it in clinical practice in the future:
1. Only one occasion of negative information can induce 
long-lasting negative clinical effects [33]. The process of 
ensuring informed consent before treatment can always 
be challenging, not only when deciding to transition 
from reference biologics to biosimilars. By definition 
the probability of an AE should be similar whether the 
patient remains on the reference biologic or switches to a 
biosimilar; informed consent of both agents would have 
similar positive aspects and negative side effects, and the 
transition should be communicated as such. Shared deci-
sion making, therefore, is critical in avoiding triggering 
a nocebo effect. Thus, an interesting ethical dilemma is 
raised about whether informing without qualification can 
compromise the Hippocratic Oath. To deliver the best 
possible care, shared decision making must be upheld 
and promoted [34], but physicians must be mindful to 
strike a balance between ethical conduct and optimal 
patient outcomes.
2. A lack of knowledge of biosimilar therapies: An interna-
tional survey was conducted to assess medication–class 
awareness, biosimilar versus reference biologic therapy 
comprehension, perceptions of clinical trials, and any 
involvement in advocacy groups. In the USA and EU, 
a clear link was demonstrated between lack of knowl-
edge and awareness of biosimilars and an increase in 
the experienced nocebo effect. Only 27% of the gen-
eral population were aware of what biosimilar products 
were, and rates of knowledge in clinicians and caregivers 
fluctuated from 45 to 78% [35, 36]. Better education 
of both HCPs and patients around biosimilar awareness 
may help reduce the likelihood of triggering a nocebo 
effect.
3. A lack of coherence between what is being communi-
cated to patients about biosimilar medications across 
Fig. 2  Global assessment 
of disease activity (NOR-
SWITCH trial) [21]. Patients 
with informed consent were 
randomised to either continue 
IFX or to transition to CT-P13. 
CT-P13 biosimilar infliximab, 
IFX originator infliximab
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healthcare by physicians, nurses, pharmacists, and oth-
ers. One solution would involve improved communica-
tion through public relations by reporting clinical and 
observational results that support the use of biosimilars.
When considering the key triggers, some basic strategies 
that can be implemented in daily clinical practice may help 
to avoid/minimise a nocebo effect.
5  Strategies for Clinical Practice
A potential strategy to improve physician–patient com-
munication consists in positive framing. Attribute fram-
ing refers to the positive versus negative description of a 
specific attribute of a single piece of information, e.g. “the 
chance of survival with cancer is 2/3” versus “the chance of 
mortality with cancer is 1/3” [37]. Improving the quality of 
physician–patient interaction/communication can minimise 
nocebo effects and optimise patient adherence [21].
In late-stage labour, before an epidural injection, women 
were told one of two things: “We are going to give you a 
local anaesthetic that will numb the area and you will be 
comfortable during the procedure” versus “You are going to 
feel a big bee sting; this is the worst part of the procedure”. 
Women reported significantly higher rates of pain associ-
ated with the second statement. Therefore, including words 
of encouragement and avoiding totally neutral statements in 
this setting has demonstrated a reduced nocebo effect and a 
lower experience of pain [38].
Physicians should strive to avoid instilling negative 
expectations during the informed consent process, proce-
dural information, and follow-up assessments so that the 
most effective physician–patient communication can be 
Table 3  Recent studies demonstrating the possible impact of the nocebo effect
AE adverse event, AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CT-P13 biosimilar infliximab, ETN 
etanercept (reference), IFX infliximab (originator), JIA juvenile idiopathic arthritis, PsA psoriatic arthritis, RA rheumatoid arthritis, SB4 biosimi-
lar etanercept, SpA spondyloarthritis
a Data from observational registry are limited by the lack of suitable control data
Reference biologic/
biosimilar biologic
Study design (phase) Indications Follow-up 
post-switch
Evidence of a possible nocebo effect
IFX/CT-P13 [27] Observational, single-
centre study (n = 39)
RA, SpA, PsA, JIA, 
chronic reactive 
arthritis
Variable Overall, 11 patients (28.2%) discontinued CT-P13 treatment, with 6 patients 
discontinuing due to subjective reasons with no objective deterioration of 
disease [27]
Author conclusion: “Subjective reasons (negative expectations) may play a 
role among discontinuations of biosimilars”
IFX/CT-P13 [28] Observational  registrya 
(n = 792)
RA, SpA, PsA 3 months Overall, 117 patients (15%) discontinued CT-P13 treatment, mainly due to 
perceived loss of efficacy (n = 51) or AEs (n = 34), although disease activity 
was largely unaffected in the majority of patients by the switch [28]
Author conclusion: “This warrants further investigation before such a non-
medical switch can be recommended”
IFX/CT-P13 [29] Observational, mul-
ticentre, prospec-
tive cohort study 
(n = 192)
RA, SpA, PsA 6 months Overall, 44 patients (23%) discontinued CT-P13 treatment, mainly due to 
perceived loss of efficacy (n = 35) and AEs (n = 23), although no changes in 
efficacy, safety, or immunogenicity were observed [29]
Author conclusion: “Patients discontinued biosimilar IFX mainly due to a 
subjective increase in BASDAI score and/or AEs, possibly explained by 
nocebo and/or attribution effects rather than pharmacological differences”
ETN/SB4 [30] Observational  registrya 
(n = 1548)
RA, PsA, and SpA Variable ~ 9% stopped treatment during 5 months’ follow-up, with reasons for with-
drawal reported as lack of effect (n = 59), AEs (n = 42), remission (n = 2), 
cancer (n = 4), death (n = 1), and other/unknown (n = 21)
Author conclusion: “Disease activity was largely unaffected in the majority 
of patients 3 months after non-medical switch to SB4 and comparable to the 
fluctuations observed in the 3 months prior to the switch. Longer follow-
up will offer additional understanding of the potential efficacy and safety 
consequences of the non-medical switch”
IFX/CT-P13 [31] Observational, single-
centre study (n = 89)
RA, PsA, and AS Variable After a median follow-up of 33 weeks, 72% of patients were still treated with 
CT-P13. Of the patients who asked to be switched back to reference product, 
13/25 presented clinical disease activity, 1 developed serum sickness, and 
11/25 presented no objective activity
Author conclusion: “During the treatment, mostly during the first couple of 
infusions, the subjective perception of an altered benefit of the treatment 
led 11 patients (12.5% of the patients who initially accepted the switch) to 
request to switchback to IFX, although they presented no variation in their 
disease activity scores”
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pursued while unwarranted and untenable nocebo responses 
can be avoided [39]. In the context of a reference biologic 
to biosimilar switch, discussion of the equality of the treat-
ments as assessed by independent regulators should be 
stressed instead of overemphasising the remote chance of a 
small difference with unknown clinical consequence.
A second important aspect is the knowledge about bio-
similars. An immediate need exists to educate HCPs and 
patients about biosimilars to ensure that informed decisions 
are made regarding use [35]. Reference to the wealth of evi-
dence available can build physician confidence (Fig. 3)—
confidence that is transferred to patients, enabling them 
to make informed choices with their physician about their 
healthcare [40].
Moreover, a managed switching programme from a refer-
ence biologic to a biosimilar may reduce possible nocebo 
effects, utilising the One Voice package [41]. The One Voice 
package provides an entire healthcare institution with guid-
ance on lexicon and language use, from receptionist to phy-
sician, to ensure a standardised, unified approach to com-
munications around biosimilar medications. This principle 
ensures that no divergent opinions are being expressed to 
patients regarding the agreed treatment strategies, and pref-
erably that all HCPs involved in their management ‘speak 
the same language’. An example of such an approach is the 
Dutch Hospital Pharmacists/Medical Specialist Biosimilars 
Toolbox, containing a project plan and training materials, 
and example letters, etc. [41].
6  Conclusions and Further Work
The nocebo effect should be taken seriously, with proper 
avoidance planning encouraged. Although examples given 
here are largely tumour necrosis factor-based, ample research 
has demonstrated that this is very much a healthcare-wide 
issue already observed for decades in a variety of disease 
and treatment situations.
Studies on factors other than perceived diminished effi-
cacy and serious AEs are warranted. These should focus on 
less tangible factors such as a priori personal beliefs (either 
those of patients or HCPs), chosen wording in informa-
tion material, flow of communication and the impact of 
patient preferences on ease of administration (i.e. injec-
tion devices). Results should clarify the potential placebo/
nocebo impact of each of these treatment-effect modifying 
factors.
We believe that successful transition programmes should 
be based on a comprehensive project plan, including training 
of all HCPs in biosimilar information and shared decision 
making, leading to a One Voice approach.
When discussing switching with patients, only the con-
cept of the biosimilar and the available evidence regarding 
efficacy (non-inferiority) and safety (no additional signals 
or immunogenicity) should be mentioned. The patient has 
already been informed of the originator efficacy and safety. 
We should address the fact that in patients with good disease 
control, transitioning can be associated with maintenance, 
Fig. 3  Translating the breadth 
of data in this field for the 
patient. Confident HCPs regard-
ing biosimilar agents result in 
empowered patient treatment 
decisions in rheumatoid arthri-
tis. HCPs aware of the depth 
and breadth of biosimilar data 
and able to explain this informa-
tion effectively to a patient will 
result in patient confidence 
in their treatment choice, 
ultimately leading to an increase 
in medication adherence 
and a reduction in the prob-
ability of a nocebo effect [42]. 
HCP healthcare professional, 
PD pharmacodynamics, PK 
pharmacokinetics. Reprinted by 
permission from the RightsLink 
Permissions Springer Customer 
Service Centre GmbH: Springer 
Nature, Rheumatology and 
Therapy, Treatment Outcomes 
with Biosimilars: Be Aware of 
the Nocebo Effect, Rezk MF 
and Pieper B, copyright 2017
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but obviously not improvement of the salutary effect of treat-
ment, as the continued treatment is essentially the same. The 
One Voice package should prevent the expression of diver-
gent opinions to patients. In this way, transition programmes 
can achieve the full potential of biosimilars—equally effec-
tive treatment at lower cost and potentially with increased 
patient access. It is a societal responsibility of each HCP to 
support these noble objectives to the benefit of a sustainable 
and affordable healthcare system.
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